Our clinical studies
We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.
Clinical studies
This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.
Title | Therapeutic area | Phase | Status | Start date | (Planned) End date |
---|---|---|---|---|---|
Phase I-II study of F17752 in patients with advanced solid tumors |
Oncology | Phase I / II | Early termination | 01 October 2013 | 13 October 2013 |
Bronchodilator properties and safety of a repeated dose of V0162 inhalation powder in asthma |
Respiratory | Phase II | Completed | 26 September 2013 | 30 April 2014 |
Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence |
Respiratory | Phase III | Completed | 02 September 2013 | 17 October 2016 |
Phase III study of Vinflunine plus Capecitabine versus Capecitabine alone in patients with advanced breast cancer |
Oncology | Phase III | Completed | September 2013 | July 2017 |
Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure |
Cardiovascular | Phase II | Completed | 20 May 2013 | 21 June 2017 |
Get access to Partner's pivotal studies supporting our authorized drugs in Europe
Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below: